Long-Term Study to Identify Biomarkers for Monitoring Eosinophilic Granulomatosis With Polyangiitis Disease Activity

What this Trial Is About

Eosinophilic granulomatosis with polyangiitis EGPA is a rare immune disorder causing asthma, high levels of eosinophils in the blood, and inflammation of blood vessels, affecting organs like skin, lungs, nerves, and kidneys. This research aims to find new biological markers, or biomarkers, to better assess how active the disease is in people with EGPA, improving disease monitoring and future treatment development. The study involves regular visits every 6 or 12 months where participants provide blood and urine samples. Each visit includes a physical exam, medical and medication history review, and completion of questionnaires about disease activity, health status, and lifestyle habits. These procedures help researchers identify biomarkers that reflect disease severity and response to treatment. Participants will be monitored over time with repeated assessments to track disease progression and biomarker levels. Researchers will analyze these data to discover markers that can predict clinical outcomes and guide care. The study aims to improve understanding of EGPA activity and support better management for patients during times when symptoms may not be obvious.

Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis